-
1 Comment
Santen Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 7.4% below its 200 day moving average.
From a valuation standpoint, the stock is 96.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.5.
Santen Pharmaceutical Co., Ltd's total revenue sank by 1.1% to $63B since the same quarter in the previous year.
Its net income has increased by 1.4% to $7B since the same quarter in the previous year.
Finally, its free cash flow grew by 274.9% to $5B since the same quarter in the previous year.
Based on the above factors, Santen Pharmaceutical Co., Ltd gets an overall score of 3/5.
| Exchange | TSE |
|---|---|
| CurrencyCode | JPY |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| ISIN | JP3336000009 |
| Target Price | 2127.7778 |
|---|---|
| Dividend Yield | 2.1% |
| Beta | 0.23 |
| Market Cap | 500B |
| PE Ratio | 14.31 |
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker for the treatment of glaucoma and ocular hypertension; and ciclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis, as well as latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative filed for marketing approval for the treatment of glaucoma and ocular hypertension; and epinastine hydrochloride, a histamine H1 receptor antagonist filed for marketing approval for the treatment of allergic conjunctivitis. The company also offers netarsudil mesylate/latanoprost, a fixed dose combination drug of a ROCK inhibitor and a prostaglandin F2a derivative which is in phase III clinical trial for the treatment of glaucoma and ocular hypertension; and sepetaprost, a prostaglandin analogue eye drop drug that is in phase III clinical trials for the treatment of glaucoma and ocular hypertension. In addition, it develops oxymetazoline hydrochloride, a direct-acting alpha adrenergic receptor agonist which is in phase III clinical trial for treatment of ptosis; and omidenepag isopropyl, an EP2 receptor agonist that is in phase III clinical trial for the treatment of glaucoma and ocular hypertension. Further, the company offers atropine sulfate, a non-selective muscarinic antagonist that is in phase II/III clinical trials for the treatment of juvenile myopia; olodaterol hydrochloride, a ß2 receptor agonist that has completed phase 1/2a clinical trial for the treatment of a dry eye; and sirolimus, an ophthalmic suspension which is in phase 2a clinical trial for the treatment of fuchs endothelial corneal dystrophy and meibomian gland dysfunction. The company was founded in 1890 and is headquartered in Osaka, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4536.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
